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Vascular stiffness is an independent risk factor for mul-tiple negative cardiovascular outcomes in normally 
aging adults, including stroke, myocardial infarction, and 
sudden death.1 Whether vascular stiffness occurs in develop-
mental cardiovascular disorders and portends similar adverse 
cardiovascular outcomes is not well documented. Previous 
investigations in mouse models have consistently linked hap-
loinsufficiency for elastin, an extracellular matrix protein 
that provides recoil to elastic tissues, to increased vascular 
stiffness and hypertension.2 Comparable data on the effect of 
elastin deficiency on vascular stiffness in humans are lacking 
and, thus, warrant study in naturally occurring elastin defi-
ciency disorders.
Loss of function defects in the human elastin gene (ELN) 
cause focal arterial stenosis, generalized vascular narrowing, 
and hypertension in a rare condition called nonsyndromic 
supravalvular aortic stenosis3–5 (SVAS; MIM No. 185500, 
prevalence 1:20 000). Deletion of an entire ELN allele as part 
of the contiguous gene deletion disorder, Williams syndrome 
(WS; MIM No. 194050, prevalence 1:8000–10 000), leads to 
the same vascular phenotype.6
To test the hypothesis that elastin insufficiency is associ-
ated with vascular stiffness in humans, we initiated the multi-
institutional Williams Syndrome-Skin And Vessel Elasticity 
(WS-SAVE) study. Using applanation tonometry, we collected 
pulse wave velocity (PWV) measurements in the single largest 
WS cohort studied to date, consisting of 77 affected individuals 
aged 7 to 62 years. Vascular stiffness normally increases with 
age and with comorbid conditions such as hypertension and 
diabetes mellitus.7 Consequently, this robust sample size and 
broad age range allowed us to evaluate the presence of vascu-
lar stiffness in WS throughout the life span and also to identify 
covariates that modify arterial stiffness in this population. In 
particular, we investigate both pharmacological interventions 
and genetic alterations that influence arterial stiffness and iden-
tify treatments associated with lower PWV. Differences in the 
WS deletion affecting copy number (CN) for NCF1, a nico-
tinamide adenine dinucleotide phosphate (NADPH) oxidase 
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subunit, have been shown to affect hypertension risk in WS,8 
but investigation of the gene’s effect on arterial stiffness has not 
been investigated. Because individuals with WS are at mark-
edly increased risk of sudden death9,10 possibly due, in part, to 
increased vascular stiffness, the modifiers examined may be 
critical to improving their health and longevity. In addition, 
these findings could inform the management of other conditions 
that lead to pediatric vascular stiffness, such as diabetes mellitus 
and chronic renal failure.11,12
Subjects and Methods
Please see Methods in the online-only Data Supplement for addi-
tional details.
Study Populations
Recruitment of cases and controls was performed as part of institu-
tional review board–approved studies (WS cases through Washington 
University School of Medicine [WUSM] and the Massachusetts 
General Hospital, adult controls through WUSM, and pediatric controls 
through Semmelweis University). Each participant (adult controls) or 
their parent/caregiver (pediatric controls and all WS cases) consented 
to participation in the study. Procedures followed were in accordance 
with institutional guidelines. Historical, medical, and surgical data 
were obtained by the use of a questionnaire. Medical records, including 
echocardiogram, were reviewed to validate questionnaire data when 
possible. Participants with WS underwent cardiovascular physical 
examination, and WS phenotype was verified on physical examination 
by experienced clinical geneticists. Molecular confirmation of WS was 
achieved either by review of clinical testing results (fluorescent in situ 
hybridization or microarray) or by research quantification of ELN CN 
(Figure S1 in the online-only Data Supplement).
Pulse Wave Velocity
Height and weight were formally measured, and individuals were 
then placed in a supine position and allowed to rest quietly. Blood 
pressure was manually assessed in both arms. PWV was determined 
from contour analysis of arterial waveforms recorded by applanation 
tonometry using a highly reproducible technique.7,13,14
NCF1 Gene and Pseudogene CN Determination
The WS critical region on chromosome 7 is flanked by 3 regions of low 
CN repeats,8,15 each containing the NCF1 gene or 1 of its 2 NCF1 pseu-
dogenes (NCF1B and NCF1C; Figure S2). The absence of 2 base pairs 
(ΔGT) at the beginning of exon 2 in the pseudogenes distinguishes them 
from the NCF1 gene.16 To calculate relative CN for the NCF1 gene to its 
pseudogenes, both the genes and pseudogenes were amplified together 
using polymerase chain reaction primers surrounding the ΔGT region. 
After polymerase chain reaction amplification, the product was gel 
purified and Sanger sequenced. At the ΔGT, the gene and pseudogene 
sequences diverge, and the relative peak heights of the next 27 bases 
are determined from the tracings as previously described.17 NCF1 gene 
and pseudogene CN were assigned using the ratio table in Table S1, and 
NCF1 gene number was used in subsequent statistical analysis.
Statistical Analyses
PWV in WS Versus Matched Controls
Because PWV normally increases with age,7,14,18 our initial analysis 
evaluated the pediatric (n=36) and adult (n=41) cohorts separately. 
Cases and controls were matched, and PWV readings were com-
pared using results from paired t tests. To determine whether PWV 
increases with age at the same rate in participants with WS versus 
controls, we also performed regression in the full-matched data set 
(n=77) with age as the covariate.
Covariate Analysis (PWV)
To identify additional features associated with higher PWV in the WS 
population, we performed regression on PWV data from participants 
with WS using diabetes mellitus, hypertension, antihypertensive 
medication, or NCF1 CN status as the covariate. For the NCF1 CN 
analysis, because of the observed protective effect of antihyperten-
sives on PWV in WS (Figure 2B) and others,19 individuals known to 
use these medications were excluded from this analysis.
Covariate Analysis (Hypertension)
The Fisher exact test was used to compare the prevalence of hyper-
tension in WS individuals with NCF1 gene CN of 1 versus ≥2. 
Hypertension was defined as any participant who had received a diag-
nosis of hypertension (treated or untreated). For each analysis, only 
participants with the necessary data components were analyzed, and 
n for each study is reported. All statistical analyses were performed 




A total of 103 individuals with WS (aged 7–62 years) were con-
sented for the WS-SAVE study. Quality PWV measurements 
were obtained in 77 of the 103 (74.8%) participants with WS. 
Rates of vascular disease in those with successful versus unsuc-
cessful PWV measurements were similar for most phenotypes 
assessed (see Table S2 for P values), with the unsuccessful 
cohort having a higher percentage of women, individuals with 
elevated body mass index (>35), and SVAS repair. No partici-
pants were fully excluded from the study, but individuals were 
excluded from portions of the analysis in which relevant data 
were not available. For example, history of hypertension was 
assessed in 101 of 103 participants. Similarly, DNA was of suf-
ficient quality to calculate NCF1 CN in 101 of 103 individuals.
Controls
Adult Controls
Adult controls (n=41; aged 21.5–62.4 years) were ambula-
tory subjects selected from participants of institutional review 
board–approved cardiovascular studies at WUSM. Subjects 
were excluded for any of the following: left ventricular sys-
tolic dysfunction (ejection fraction <55%), reported or sus-
pected coronary artery disease, pulmonary hypertension, 
stage C or worse chronic kidney disease, reported infection by 
the HIV, and reported sickle cell disease. Adults were matched 
to participants with WS, in aggregate, for body mass index, 
hypertension diagnosis, use of antihypertensives, and diabetes 
mellitus, in addition to age and sex (paired t tests revealed 
nonsignificant results for these variables; Table S3).
Pediatric Controls
Pediatric controls (n=36; aged 7.6–21.2 years) were enrolled as 
part of an international study establishing reference values of 
PWV in children and adolescents.18 Children with known history 
of hypertension or diabetes mellitus were excluded. Children were 
matched by age (mean difference±SD [WS-C], 0.04±0.19 years), 
sex, and height (mean difference [WS-C] −6±7 cm) to WS youth.
Clinical Characteristics of the WS-SAVE Cohort
To determine whether the increased arterial stiffness noted in 
elastin-insufficient mice20–22 extrapolates to humans with elas-
tin insufficiency, we attempted PWV in a cohort of 103 individ-
uals with WS. Clinical features of the 77 subjects successfully 
completing the PWV portion of the study are included in Table 
S4. Sixty-nine percent of those with successful PWV mea-
surements have a history of vascular stenosis (any location). 
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Fifty-four percent had SVAS, but only 10% had SVAS requir-
ing surgical intervention. Forty percent of the cohort reported 
a history of hypertension, but only 25% had hypertension that 
was treated with antihypertensive medication. Ten percent 
reported a diagnosis of diabetes mellitus. Stroke (any type) was 
reported in 6% (3/48) of all individuals asked about this pheno-
type; among the subset with a successful PWV measurement, 2 
of 36 (6%) reported a history of stroke.
Children and Adults With WS Show Stiffer Vessels 
Than Matched Controls
PWVs from the 77 individuals with WS were compared with 
pediatric and adult controls. When the pediatric subset was 
compared in paired t tests, those with WS were found, on aver-
age, to have significantly higher PWV (mean±SD, 6.1±1.0 
[WS] versus 5.1±0.8 m/s [control]; P<0.0001; Figure 1A). 
Increased PWV was obvious in even the youngest participants 
with WS (see Figure S3A for raw WS data plotted against 
healthy population control means).14,18 In adults, paired t tests 
again showed higher PWV in WS adults (7.5±1.8 m/s, WS) 
versus controls (6.9±1.1 m/s, controls; P=0.02; Figure 1B).
PWV normally increases with age.7,18 To evaluate for pos-
sible differential effects of aging on PWV in WS, regression 
was performed using the full WS data set and matched controls 
(n=77 each). This analysis showed higher PWVs in participants 
with WS across the whole age distribution (P<0.0001 for eleva-
tion), with no statistical difference in the rate of PWV increase 
with age compared with controls (P=NS for slope; Figure S3B).
PWV: WS Clinical Phenotypes Associated With 
Vascular Stiffness
We sought to determine whether hypertension and diabetes 
mellitus, previously linked to increased vascular stiffness in 
non-Williams cohorts,7,23,24 were associated with higher PWV 
in WS. Regression analyses showed no significant relation-
ship between PWV and hypertension (treated and untreated; 
Figure 2A) or diabetes mellitus (Figure S4). We did, however, 
see relative protection from increased PWV in WS individuals 
taking antihypertensives (P=0.001; Figure 2B). Of note, 58% 
(21/36) of those with PWV >1 m/s higher than the popula-
tion mean for age and sex14,18 had no history of hypertension, 
whereas 36% (4/11) of those with reported untreated hyper-
tension did not show elevated PWV.
Decreased NCF1 Gene CN Protects From Vascular 
Stiffness in WS
We investigated whether NCF1 CN was also associated with 
changes in vascular stiffness, as predicted by quantitative trait 
Figure 1. Pediatric cases and adults with Williams syndrome (WS) 
have higher pulse wave velocity (PWV) than matched controls. 
PWV was measured in WS pediatric cases (n=36; aged 7.6–21.2 
years) and adults (n=41; aged 21.5–62.4 years). When compared 
in paired t tests, youth with WS were found, on average, to have 
significantly higher PWV (A). The WS adults were compared with 
those with a similar compilation of hypertension, diabetes mellitus, 
antihypertensive medication use, and body mass index, in addition 
to matched age and sex, and also had higher PWV (B). Controls 
are black, and participants with WS are gray. The box shows the 
SD with the mean PWV marked inside the box. The whiskers on 
the boxes depict the extreme reach of the PWVs measured.
Figure 2. Use of antihypertensives, but not hypertension, influences 
the severity of vascular stiffness in Williams syndrome (WS). 
Regression analyses were performed by plotting WS participant 
data points by age and pulse wave velocity (PWV) and dividing the 
cohort by history of hypertension (A; n=76, 30 with hypertension 
[HTN] and 46 without HTN) or use of antihypertensive medications 
(B; n=76, 22 using medication [meds] and 54 not using medication). 
Data from participants without the described feature are gray, and 
those with the phenotype are black. Regression lines are shown. 
The slope of the regression line was significantly different only in 
B, in which the use of antihypertensive medication seems to be 
protective from increases in PWV (P=0.001).
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analysis in the Eln+/− mouse.25 Regression analysis showed 
higher PWVs in participants with WS who had ≥2 copies of 
NCF1 rather than 1 (P=0.05 for elevation; Figure 3). There 
was no statistical difference in the rate of PWV increase 
with age (P=NS for slope) in individuals with CN=1 or 2 in 
this analysis. Interestingly, removal of the single participant 
with the highest PWV (denoted by #) increases the differ-
ence in PWV observed between CN=1 and CN=2 individuals 
(P=0.005 for elevation), with a trend toward better protection 
from increasing PWV with older age (P for slope improves 
from 0.6 to 0.1; Figure S5).
NCF1 Gene CN and Hypertension in WS
To determine whether the deletion of NCF1 affected hyperten-
sion in our cohort, we compared the frequency of hyperten-
sion between WS individuals with 1 versus ≥2 NCF1 genes. 
In our total cohort of 99 individuals with WS in whom both 
NCF1 CN and hypertension status were known, a single copy 
of NCF1 was associated with protection from hypertension 
(P=0.03; Figure S6). This association persisted even when 
restricting the analysis to those aged <18 years (P=0.04; data 
not shown) in which the WS-related component of hyperten-
sion may be more dominant. These results confirm the pre-
viously reported protective association of reduced NCF1 CN 
and risk of hypertension in WS.8
Discussion
In a developing blood vessel, collagen is responsible for ten-
sile strength, whereas elastin provides recoil capability. When 
the elastin gene is mutated or deleted, the resulting elastin 
insufficiency leads to multiple cardiovascular abnormalities. 
Most consistently described in these populations are focal 
arterial stenoses and hypertension.5,6,26,27 However, the sever-
ity of the vascular features in WS is variable. The frequency 
of WS-associated vascular symptoms in WS-SAVE is simi-
lar to previous reports,6,28 with history of SVAS in 55% and 
hypertension in 40%. Importantly, only 25% of the cohort 
reported using antihypertensive medication for blood pres-
sure control. Decision to treat was made by each individual’s 
primary medical team and may reflect overall population 
undertreatment or possible hesitancy to treat hypertension in 
syndromic individuals in whom high blood pressure measure-
ments are often felt to represent anxiety in the medical setting. 
Interestingly, studies on this question have shown a paucity of 
true white coat hypertension in this population.28
Previous investigations of vascular stiffness in WS yielded 
contradictory results, ranging from increased arterial stiff-
ness29,30 to normal or even paradoxically reduced values31,32 in 
small studies consisting of 3 to 29 participants. Consistent with 
these reports and with other cardiovascular features in WS, our 
larger analysis found considerable interpersonal PWV vari-
ability. However, even with this variability, individuals with 
WS had significantly stiffer vessels than matched controls. As 
in the Eln+/− mouse, this stiffness is apparent from the earliest 
ages studied20,33 and progresses with increasing age at the same 
rate as controls, suggesting that elastin insufficiency causes 
early-onset and possibly congenital arterial stiffness. Eln+/− 
mice generally become hypertensive in the neonatal period, a 
process suggested to be a physiological response to the altered 
vascular mechanics brought on by elastin insufficiency.21 
In many of our cases, vascular stiffness was present without 
hypertension, and conversely, in some cases, hypertension was 
present without stiffness, suggesting that the 2 features may 
be related but independent effects of elastin insufficiency. For 
some of the studied individuals, increased PWV is the only 
known cardiovascular manifestation of the disorder. The devel-
opment of hypertension in WS is likely multifactorial with 
influences due to vascular stiffness, complex effects of genetic 
background, and other features of WS such as renal artery ste-
nosis and small-for-gestational-age birth.28
Our data show that vessels of pediatric participants with WS 
are more uniformly stiff than matched controls. Greater vari-
ability is seen in older participants with WS, with evidence of 
protection in those on antihypertensive medications. The mean 
PWV observed in pediatric participants with WS is 6.1 m/s, 
approaching that seen in predialysis youth with end-stage renal 
disease (6.6 m/s)11 and youth with type 2 diabetes mellitus (6.4 
m/s12, both with similar age demographics). Interestingly, in the 
end stage renal disease study, no improvement resulted from 
hemodialysis, suggesting a final common pathway to these 
conditions ending in destruction of elastic matrices and lasting 
alteration of the biomechanical properties of the vessel wall.
The fact that we did not see a primary hypertension-by-
PWV effect in regression analysis may result from an admix-
ture of untreated hypertensive individuals (who generally have 
higher PWVs) with treated hypertensive WS participants (in 
whom our data show lower PWVs). This mixing may ulti-
mately act to normalize the PWV for the hypertensive group, 
causing it to appear similar to the nonhypertensive subset. 
Further subgroup analysis, however, was underpowered. The 
use of antihypertensive medication showed greater protection 
in older individuals with WS, possibly suggesting cumulative 
effects of longer treatment duration; however, longitudinal 
evaluation is needed to confirm this.
Because vascular stiffness is strongly associated with 
negative cardiovascular consequences, such as myocardial 
infarction and stroke,1 further investigation into the predic-
tive power of PWV for clinical outcome in individuals with 
Figure 3. NCF1 copy number (CN) modifies vascular disease 
severity in Williams syndrome. Regression analysis is used to 
assess the effect of NCF1 CN on pulse wave velocity (PWV; 
n=55). Those with NCF1 CN ≥2 (black) have higher PWV 
than those with CN=1 (gray; P=0.05 for elevation), but there 
is no difference in the increase in stiffness over time in this 
cohort (P=NS for slope). # denotes the single participant with 
CN=1 outlier.
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WS is warranted. In our study, 48 participants were surveyed 
about their stroke history, and 3 of 48 (6%), aged 22, 32, and 
32 years, reported a history of stroke. The prevalence of age-
adjusted stroke for control individuals aged 18 to 45 years is 
0.6% to 0.7%34 compared with 12% (3/25) when we consider 
only the subset of participants with WS in this demographics. 
In 2 of 3 WS participants with stroke, we obtained successful 
PWV measurements, and both were elevated (+0.6 and +1.4 
m/s relative to age- or sex-matched controls), although both 
participants were receiving antihypertensive medications at 
the time of PWV measurement. Currently, the best estimate of 
risk of sudden death in WS is 25- to 100-fold increased rela-
tive to the general population.10 It is likely that this risk does 
not apply equally to all individuals with WS, and the use of 
PWV may enable individualized risk assessment. Full details 
about the nature of strokes in these participants are not avail-
able, and further investigation into this area is warranted.
Because of its status as a variably deleted gene in WS, NCF1 
CN was investigated and found to be a significant modifier of 
arterial stiffness in WS. Data from the current cohort also con-
firm the reduced risk of hypertension associated with NCF1 
CN=1 originally described by Del Campo et al.8 Although our 
study found generally lower PWVs in WS participants with 
only 1 copy of NCF1 relative to those with ≥2, initial analysis 
revealed no difference in the rate of age-associated increase in 
PWV between the 2 groups. However, when a single outlier is 
removed, a trend toward progressive protection with advancing 
age is identified in those with CN=1. Because NCF1 is a mem-
ber of the NADPH oxidase family and is involved in the genera-
tion of reactive oxygen species in tissues,35 its association with 
severity of vascular stiffness suggests a role for chronic oxidative 
stress in the pathology of vascular stiffness in WS. Additional 
studies with focused recruitment of older individuals with WS, 
although difficult, may help clarify this intriguing finding.
Limitations of our study include the possibility that because 
of the topic of the study, parents of individuals with signifi-
cant vascular disease were more interested in participating. 
However, our study includes many subjects with no previ-
ously known vascular features of WS (who, in fact, have high 
PWV). Second, challenges inherent to WS limited the number 
of successful PWV studies we were able to obtain. Individuals 
with WS have an average intelligence quotient of 55 and are 
often anxious, making it difficult to obtain resting measure-
ments in younger children with WS. High body mass index, 
in combination with these features, additionally complicated 
PWV acquisition in some adults. Reassuringly, phenotypes of 
participants on whom we failed to obtain PWV trended toward 
more severe vascular disease with higher rates of hypertension 
and stenosis seen in this group. These findings suggest that 
it is unlikely that the data loss excluded a milder cohort that 
might skew the PWV results. Finally, our studies are merely a 
single snapshot in time. To investigate the interaction between 
vascular stiffness and hypertension in elastin insufficiency, 
additional larger prospective studies are needed to document 
the natural evolution of these phenotypes.
Perspectives
This study successfully evaluated vascular stiffness in the 
largest cohort of individuals with WS reported to date and 
demonstrates that individuals with WS, regardless of their 
blood pressure, are at risk for increased aortic stiffness, a well-
established surrogate for adverse cardiovascular outcomes in 
many disease processes. This increase in vascular stiffness is 
caused by elastin insufficiency, as evidenced by Eln+/−mouse 
studies20–22 and, importantly, is modified by antihypertensive 
use and NCF1 CN. PWV differences are detectable at the ear-
liest ages studied and continue into adulthood, making WS 
and elastin insufficiency useful models in which to study the 
long-term effects of chronic and early-onset vascular stiffness. 
Overall, this study suggests that (1) monitoring of vascular stiff-
ness is warranted in WS; (2) antihypertensive treatment might 
protect against vascular stiffness and consequent adverse car-
diovascular events in individuals with WS, even without overt 
hypertension. Consequently, at a minimum, antihypertensives 
should be considered in all WS individuals with hypertension; 
and finally, (3) novel medications, aimed at the NADPH oxi-
dase pathway, should be investigated as potential modulators 
of vascular disease severity in this condition with use poten-
tially determined by NCF1 CN. To generate formal treatment 
guidelines, larger prospective studies are needed to quantify the 
effects of antihypertensive drug choice and duration in treating 
arterial stiffness in WS. In addition, more work is needed to bet-
ter understand the prognostic relevance of early-onset vascular 
stiffness in those with WS, with special attention given to organ 
systems known to be adversely affected in aging adults with 
vascular stiffness, such as the kidneys, heart, and brain. Finally, 
medication by NCF1 CN studies are needed to determine which 
patients may most benefit from pharmacological intervention.
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What Is New?
•	The Williams Syndrome (WS)-Skin And Vessel Elasticity study is the larg-
est multi-institutional study of vascular stiffness in Williams syndrome 
to date, revealing increased pulse wave velocity in individuals with this 
rare condition.
What Is Relevant?
•	 Increased pulse wave velocity was identified in even the youngest Wil-
liams participants, suggesting that vascular stiffness is of early, if not 
congenital, onset. Stiffness seems to be independent of hypertension in 
WS, making vascular stiffness a new primary WS phenotype. Protection 
against increasing stiffness is afforded by antihypertensive medication 
and also by deletion of NCF1, an NADPH oxidase component and gene 
variably deleted in WS.
Summary
Elastin insufficiency causes increased arterial stiffness, a pheno-
type associated with multiple negative cardiovascular outcomes 
complicating WS. Elevated pulse wave velocity is seen less often in 
those with WS deletions also removing the NCF1 gene and in those 
on antihypertensive therapy. Our findings suggest the need for en-
hanced evaluation and anticipatory treatment of vascular disease 
in Williams syndrome.
Novelty and Significance
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2:3  0.68‐0.78  5  0 
3:3 or 2:2   1.04‐1.07  2  2 
3:2  1.35‐1.95   47  0 
4:2/2:1  1.96‐2.15  0  7 








































Age  (years)  24.1 (7‐54)  24.6 (7‐62)  0.85 













































































Age  BMI  Hx of HTN (%)  Use of HTN Meds (%)  Diabetes (%) 
Control  33.9  27.4 44 29  13
WS  33.7  25.7 49 34  18





































































HTN   30/76  4/10  6/22  6/23  9/12  4/6  2/3 
HTN 
Meds*   22/76  3/10  5/22  3/23  5/12  4/6  2/3 
Meds for 
HTN   19/76  3/10  3/22  3/23  5/12  4/6  1/3 
Any 
Stenosis  49/71  8/10  15/20  15/21  7/11  3/6  1/3 
SVAS         38/70  6/10  11/20  12/21  7/11  3/6  0/2 
Surgical 
SVAS  7/65  1/10  2/19  2/18  2/11  0/5  0/2 
Diabetes    7/73  0/10  0/22  1/21  3/11  2/6  1/3 
Known 


















































































Gyorgy S. Reusz, Eva Kis, Ami B. Bhatt and Barbara R. Pober
Beth A. Kozel, Joshua R. Danback, Jessica L. Waxler, Russell H. Knutsen, Lisa de las Fuentes,
NCF1and Copy Number Changes in 
Williams Syndrome Predisposes to Vascular Stiffness Modified by Antihypertensive Use
Print ISSN: 0194-911X. Online ISSN: 1524-4563 
Copyright © 2013 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Hypertension 
doi: 10.1161/HYPERTENSIONAHA.113.02087
2014;63:74-79; originally published online October 14, 2013;Hypertension. 
 http://hyper.ahajournals.org/content/63/1/74
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://hyper.ahajournals.org/content/suppl/2013/10/14/HYPERTENSIONAHA.113.02087.DC1.html
Data Supplement (unedited) at:
  
 http://hyper.ahajournals.org//subscriptions/
is online at: Hypertension  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialHypertensionin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at Semmelweis University (Egyetem) on January 13, 2015http://hyper.ahajournals.org/Downloaded from 
